Allan Young
Professor of Psychiatry
Data updated
Research Footprint
Allan Young appears in 21 tracked papers (2016–2026), most studied alongside Psilocybin, Ketamine and Esketamine, across Depressive Disorders, Treatment-Resistant Depression (TRD) and Major Depressive Disorder (MDD).
Most-cited paper: Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression (1057 citations).
Frequent co-authors: James Rucker, Luke Jelen and Guy Goodwin.
Background & Research
Allan H. Young is a psychiatrist and academic whose work spans mood disorders, psychopharmacology and translational clinical research. He has led and contributed to a range of clinical studies and reviews examining rapid-acting antidepressants and psychedelic compounds, with particular emphasis on treatment‑resistant depression, neuroimaging correlates of treatment response, and the safety and tolerability of novel interventions. He has been an investigator on randomized and feasibility trials (including protocols for psilocybin-assisted therapy), phase‑1 studies of intranasal DMT formulations, and secondary analyses comparing esketamine with other pharmacotherapies in treatment‑resistant depression. He has also contributed to syntheses of the evidence base for ketamine and esketamine and to reviews of classical psychedelics such as ayahuasca.
Key Impact
A senior clinical psychiatrist and researcher who has helped translate psychedelic and rapid-acting psychopharmacological interventions into clinical research for treatment-resistant mood disorders.
Collaboration Network
61 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Allan Young is associated with.
Imperial College London
academicThe Centre for Psychedelic Research, led by Professor David Nutt and Dr. David Erritzoe, focuses heavily on the action of psychedelic drugs in the brain and their clinical utility as aides to psychotherapy. Thanks to their extensive neuroimaging studies, this group has proposed vital mechanisms for how psychedelics work, including the Entropic Brain Theory and REBUS (RElaxed Beliefs Under Psychedelics).
View stakeholder →South London and Maudsley NHS Foundation Trust
South London and Maudsley NHS Foundation Trust (SLaM) is the UK's leading academic mental health Trust, home to Maudsley Hospital and the NIHR Maudsley Biomedical Research Centre; in partnership with COMPASS Pathways and King's College London's Institute of Psychiatry, it has established a dedicated Psychedelics and Mental Health Research Centre conducting psilocybin Phase 3 trials for treatment-resistant depression, MDMA therapy for PTSD, 5-MeO-DMT studies, and the SIGNATURE synaptic imaging biomarker trial, aiming to treat 650–700 patients over five years.
View stakeholder →COMPASS Pathways
Public BiotechCOMPASS Pathways is a UK-listed biopharmaceutical company developing COMP360 synthetic psilocybin therapy for treatment-resistant depression, with two successful Phase 3 trials making it the leading candidate for the first regulatory approval of a classic psychedelic medicine.
View stakeholder →